GLMD Galmed Pharmaceuticals Ltd.
Price Chart
Executive Summary
Galmed Pharmaceuticals announced preclinical results from a collaboration with Tissue Dynamics, identifying a previously unknown metabolic pathway for cardiac fibrosis and demonstrating that a combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p<0.001) in human cardiac organoid models. A new patent application has been filed and IND-enabling activities are being prepared. This is an early-stage preclinical finding with no clinical data or regulatory milestones yet.
Actionable Insight
This is an early-stage preclinical announcement with no near-term catalyst for revenue or clinical data. Monitor for future IND filings or partnership developments, but no immediate trading action is warranted.
Key Facts
- Preclinical study in human cardiac organoids showed combination of Aramchol Meglumine and PPARα agonist reduced fibrotic burden by ~4-fold (p<0.001)
- A new patent application has been filed based on these findings
- Preparations are underway to support future IND-enabling activities
- Galmed is a clinical-stage biopharmaceutical company with a $5M market cap
- No financial terms, revenue, or clinical trial data were disclosed in this filing
Financial Impact
No financial impact disclosed; preclinical research stage with no revenue or clinical milestones
Risk Factors
- Preclinical results may not translate to human clinical outcomes
- No clinical trial data or regulatory milestones yet
- Company has a very small market cap ($5M) and limited financial resources
- Forward-looking statements subject to significant risks and uncertainties
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-026756 |
| Document: form6-k.htm | 0001493152-26-026756 |
| Document: 0001493152-26-026756-index-headers.html | 0001493152-26-026756 |
| Document: 0001493152-26-026756-index.html | 0001493152-26-026756 |
| Document: 0001493152-26-026756.txt | 0001493152-26-026756 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
6-K
| $0.6838 awaiting T+1 | awaiting T+1 | — | $0.6120 (−10.50%) |
|
Jun 2, 2026
10d ago
|
6-K
| $0.6910 $0.6800 | ▼ −1.59% | ▼ −0.90% | $0.6120 (−11.43%) |
|
May 14, 2026
29d ago
|
6-K
| $0.6590 $0.6000 | ▼ −8.95% | ▼ −7.73% | $0.6120 (−7.13%) |
|
May 6, 2026
5w ago
|
6-K
| $0.6280 $0.6260 | ▼ −0.32% | ▲ +0.01% | $0.6120 (−2.55%) |
|
Apr 14, 2026
8w ago
|
6-K
| $0.7090 $0.7020 | ▼ −0.99% | ▼ −1.76% | $0.6120 (−13.68%) |
|
Apr 9, 2026
9w ago
|
6-K
| $0.7850 $0.7410 | ▼ −5.61% | ▼ −5.54% | $0.6120 (−22.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access